EAU 2014 - Poster: Impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Dirk L. Schrijvers,1 Thian Kheoh,2 Margaret K. Yu,2 Matthew R. Smith,3 Eric J. Small,4 Peter F.A. Mulders,5 Karim Fizazi,6 Dana E. Rathkopf,7 Fred Saad,8 Howard I. Scher,7 Stephane Oudard,9 Joaquim Bellmunt,10 Mary-Ellen Taplin,10 Ian D. Davis,11 Andrew Protheroe,12 Arturo Molina,13 Thomas W. Griffin,2 Johann S. de Bono,14 and Charles J. Ryan4 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

.Abiraterone-EAU-Schrijvers-poster thumb

1ZNA Middelheim Oncology Clinic, Antwerp, Belgium; 2Janssen Research & Development, Los Angeles, CA; 3Harvard Medical School and Massachusetts General Hospital, Boston, MA; 4Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; 5Radboud University Medical Centre, Nijmegen, The Netherlands; 6Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 7Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; 8University of Montréal, Montréal, QC, Canada; 9Georges Pompidou Hospital, Paris, France; 10Dana-Farber Cancer Institute, Boston, MA; 11Monash University and Eastern Health, Victoria, Australia; 12Churchill Hospital, Oxford, United Kingdom; 13Janssen Research & Development, Menlo Park, CA; 14The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, United Kingdom

Click HERE to read an exclusive report by a UroToday medical writer